Royalty Pharma shares soar 57% in Nasdaq debut
By C Nivedita, Joshua Franklin and Rebecca Spalding (Reuters) - Shares of Royalty Pharma Plc jumped 57.1% in their Nasdaq debut on Tuesday, another sign that demand for new stocks has recovered after the coronavirus crisis had stalled potential listings. Royalty Pharma's shares opened at $44, valuing the company at $26.2 billion. They traded up more than 53% at $42.92 at midday.
By C Nivedita, Joshua Franklin and Rebecca Spalding
(Reuters) - Shares of Royalty Pharma Plc jumped 57.1% in their Nasdaq debut on Tuesday, another sign that demand for new stocks has recovered after the coronavirus crisis had stalled potential listings.
Royalty Pharma's shares opened at $44, valuing the company at $26.2 billion. They traded up more than 53% at $42.92 at midday.
The company on Monday sold shares at $28 each to raise $2.18 billion, making it the second-largest pharmaceutical listing ever and 2020's largest U.S. listing so far.
There was more than $20 billion in orders for the IPO, according to a person familiar with the matter.
Royalty Pharma buys the royalties of future drugs from academic labs and biotechnology companies, which in turn use the cash to fund their research.
The financing will allow the company to make even bigger investments in drug research, which can cost billions in its final stages, Chief Executive Officer Pablo Legoretta said.
The company, founded in 1996, has attained certain rights of some of the world’s best-selling drugs, including Biogen's multiple sclerosis therapy, Tecfidera, Vertex's cystic fibrosis drugs, and AbbVie's Humira.
"It's a really exciting time because it's a golden age for academic and medical research," Legoretta said in an interview.
Legoretta said the coronavirus outbreak has shown a renewed light on the importance of the industry’s research. Royalty Pharma is in discussions with several academic labs about potentially helping to fund their research on COVID-19 therapies, Legoretta said.
A perception that the pharmaceutical industry is immune to broader market swings has supported investor demand, according to William Ford, chief executive of private equity firm General Atlantic, an investor in Royalty Pharma.
"The demand for pharmaceuticals is not correlated with financial markets," said Ford, who is also a Royalty Pharma director.
"We did have a view that this is a company that could have a successful IPO even in a difficult environment. Investors recognized that," Ford added.
(Reporting by C Nivedita in Bangalore and Joshua Franklin and Rebecca Spalding in New York; Editing by Vinay Dwivedi and Dan Grebler)
This story has not been edited by Firstpost staff and is generated by auto-feed.
By Robin Emmott and John Irish | BRUSSELS/PARIS BRUSSELS/PARIS France and Germany will agree to a U.S. plan for NATO to take a bigger role in the fight against Islamic militants at a meeting with President Donald Trump on Thursday, but insist the move is purely symbolic, four senior European diplomats said.The decision to allow the North Atlantic Treaty Organization to join the coalition against Islamic State in Syria and Iraq follows weeks of pressure on the two allies, who are wary of NATO confronting Russia in Syria and of alienating Arab countries who see NATO as pushing a pro-Western agenda."NATO as an institution will join the coalition," said one senior diplomat involved in the discussions. "The question is whether this just a symbolic gesture to the United States
BEIJING Chinese President Xi Jinping on Wednesday called for greater efforts to make the country's navy a world class one, strong in operations on, below and above the surface, as it steps up its ability to project power far from its shores.China's navy has taken an increasingly prominent role in recent months, with a rising star admiral taking command, its first aircraft carrier sailing around self-ruled Taiwan and a new aircraft carrier launched last month.With President Donald Trump promising a US shipbuilding spree and unnerving Beijing with his unpredictable approach on hot button issues including Taiwan and the South and East China Seas, China is pushing to narrow the gap with the U.S. Navy.Inspecting navy headquarters, Xi said the navy should "aim for the top ranks in the world", the Defence Ministry said in a statement about his visit."Building a strong and modern navy is an important mark of a top ranking global military," the ministry paraphrased Xi as saying.